

Elranatamab (Elrexfio[®])

Treatment Guide

What is elranatamab?


Elranatamab also known as Elrexfio[®], is an immunotherapy used in the treatment of myeloma. It belongs to a class of immunotherapies called bispecific antibodies.

How does it work?

Elranatamab works by using cells from the body's own immune system, called T cells. These T cells can kill abnormal cells in the body, including myeloma cells.

Elranatamab binds to proteins on the surface of the T cells and proteins on myeloma cells at the same time.

Once bound together, the T cells and myeloma cells are brought into close contact. The T cells then become active and kill the myeloma cells.



How is elranatamab given?



Elranatamab is given as a subcutaneous injection (under the skin).



Elranatamab is usually given on its own (monotherapy).



Elranatamab is usually given in increasing doses for the first 2 weeks. You will have 2 doses in your first week, then the full dose, once a week from week 2. After 6 months, you may have it once every 2 weeks.



Elranatamab is normally given until your myeloma starts to become more active. Individual treatment plans vary, your healthcare team will discuss your specific plan.

Possible side effects

Elranatamab has a number of possible side effects which can vary from patient to patient. You will experience some side effects, but it is unlikely you will experience all of them, and most side effects will ease once treatment has finished. Always report any side effects to your healthcare team as soon as possible so they can be treated quickly.

The side effects listed here are those experienced most often. For a complete list of side effects please refer to the patient information leaflet which is included in the pack with the treatment. If you do not have this, ask your healthcare team for it.



Myeloma UK provides a wide range of information booklets about side effects and their management. Relevant booklets are signposted beneath each side effect on the following pages.

You can find these along with all of our information booklets online at myeloma.org.uk/library.

You can also find out more about the management of these side effects by asking your healthcare team or by contacting Myeloma UK.



0800 980 3332



AskTheNurse@myeloma.org.uk



myeloma.org.uk



Risk of infection

Elranatamab may affect your immune system, increasing your risk of infection. Common signs include: high or low temperature (37.5°C or above, or below 36°C), feeling shivery or cold, passing urine more often or pain when passing urine, and cough or cold symptoms.



Infections can become serious if not treated quickly. Contact your healthcare team or out of hours service immediately if you think you have an infection.



For more information see the **Infection and myeloma Infosheet** from Myeloma UK.



Infusion reaction (cytokine release syndrome)

This is a common side effect of elranatamab and usually occurs within a few hours of having treatment. Symptoms include: chills, fever, fast heartbeat, feeling short of breath and feeling dizzy. You will be given medicines alongside your elranatamab to reduce the risk of an infusion reaction. If you notice any of these side effects, report them to your healthcare team immediately.



Nervous system problems

Elranatamab can cause changes to your nervous system known as Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS). This can cause symptoms including: feeling confused, feeling less alert, and difficulty writing or speaking.



If you think you have ICANS symptoms, contact your healthcare team or out of hours service immediately.



Peripheral neuropathy

Elranatamab can cause damage to nerves in the hands, feet, arms or legs. This is called peripheral neuropathy. This causes numbness, tingling and pain often in the hands or feet. These sensations can be eased with gentle massage, using hot or cold packs and nerve painkillers such as gabapentin and pregabalin. Symptoms generally improve or disappear after the dose of elranatamab is reduced or stopped.



For more information see the **Peripheral neuropathy Infosheet** from Myeloma UK.



Anaemia and bleeding

Elranatamab can decrease the number of red blood cells, causing anaemia. Symptoms include: looking pale, shortness of breath and fatigue. Elranatamab can also decrease the number of platelets, increasing your risk of bleeding or bruising. Treatment for these side effects can ease symptoms and boost your blood cell counts.



For more information see the **Fatigue and myeloma Infoguide** and **Thrombocytopenia and myeloma Infosheet** from Myeloma UK.



Gut problems

Elranatamab can cause diarrhoea. Try to drink at least 2 litres (3–4 pints) a day to prevent dehydration. You may also be prescribed medicine to reduce the diarrhoea.

Elranatamab may also cause nausea. You may be given anti-sickness (anti-emetic) medicine to prevent or reduce nausea. You must take them as prescribed rather than waiting until you feel sick. There are several types of anti-sickness medicine and if the one you have is not effective, ask to try another.

Nausea and diarrhoea may also reduce your appetite. If you start losing weight, or are concerned about your appetite, ask to be referred to a dietician. They may be able to offer high-calorie food and drink supplements.



For more information see the **Gastrointestinal disturbances Infosheet** from Myeloma UK.



Fatigue

Fatigue is a feeling of extreme tiredness that is not fully relieved by sleep. It usually resolves after treatment has finished. Your treatment, any side effects and your mental health can all impact fatigue. It can be managed by treating any medical causes such as anaemia. Allowing time for rest, regular gentle exercise and complementary therapies such as massage may also help.



For more information see the **Fatigue and myeloma Infoguide** from Myeloma UK.



Headaches

Elranatamab can cause headaches. Try to drink plenty of fluids and speak to your healthcare team about suitable painkillers.

Important information about elranatamab



You must not take elranatamab during pregnancy as it is not known if it is safe for the baby. If you or your partner could become pregnant, you must use effective contraception during treatment, and for 6 months after treatment has finished.



You should not breastfeed when taking elranatamab and for 6 months after treatment has finished, as it is not known if it could pass to the milk.



Elranatamab may make you feel dizzy or confused. You shouldn't drive or operate heavy machinery for at least 48 hours after your first 3 doses, or until advised by your healthcare team.



Supplements or herbal medicines that have not been prescribed by your haematologist may cause harm when taken alongside your prescribed treatment.

You must speak to your healthcare team before taking any kind of supplement or alternative treatment, including herbal, traditional or natural medicines and remedies, and vitamins or wellbeing supplements, to ensure it is safe to do so.



If you have any questions about your treatment, speak to your healthcare team. They are the best people to ask if you have questions about your individual situation. The information in this publication is not meant to replace their advice.



Treatment Guide: Elranatamab (Elrexfio®)



We're here for everything a diagnosis of myeloma brings

Get in touch to find out more about how we can support you

Call the Myeloma Infoline on



0800 980 3332

Email Ask the Nurse at




AskTheNurse@myeloma.org.uk

Visit our website at



myeloma.org.uk



Myeloma UK

22 Logie Mill, Beaverbank Business Park,
Edinburgh EH7 4HG



0131 557 3332



myelomauk@myeloma.org.uk

Registered Charity No: SC026116

Published by:	Myeloma UK
First published:	December 2024
Next review due:	December 2027



We appreciate your feedback

Please fill in a short online survey about our patient information
at **myeloma.org.uk/pifedback** or email any comments to
patientinfo@myeloma.org.uk



For a list of references used to develop our resources, visit
myeloma.org.uk/references